Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Does paraneoplastic porphyria cutanea tarda exist?].

E Köstler1

  • 1Hautklinik, Bezirkskrankenhauses Dresden-Friedrichstadt.

Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten
|January 1, 1988
PubMed
Summary

Porphyria cutanea tarda (PCT) is typically not a cancer symptom. However, long-term PCT may increase liver cancer risk, but chloroquine phosphate therapy might prevent this progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioluminescence, chemiluminescence.

Fresenius' journal of analytical chemistry·2020
Same author

Does chloroquine therapy of porphyria cutanea tarda influence liver pathology?

International journal of dermatology·2010
Same author

[Reader's letter on Marcus Meissner, Jens, Gille, Roland Kaufmann. Calciphylaxis: no therapeutic concepts for a poorly understood syndrome?].

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2007
Same author

Cutaneous Langerhans cell histiocytosis with subsequent development of haematological malignancies. Report of two cases.

Acta dermatovenerologica Alpina, Pannonica, et Adriatica·2006
Same author

Treatment of dystrophic calcification in leg ulcers.

International wound journal·2006
Same author

[Hepatitis C, hemochromatosis and porphyria cutanea tarda].

Deutsche medizinische Wochenschrift (1946)·2006

Area of Science:

  • Hepatology
  • Dermatology
  • Oncology

Context:

  • Porphyria cutanea tarda (PCT) is a metabolic disorder affecting the liver and skin.
  • The relationship between PCT and cancer, particularly paraneoplastic dermatoses, requires clarification.
  • Distinguishing PCT from other conditions with similar presentations is crucial for accurate diagnosis and management.

Purpose:

  • To investigate the association between porphyria cutanea tarda and various types of tumors.
  • To determine if PCT is a paraneoplastic dermatosis or if it correlates with specific cancers.
  • To evaluate the potential role of chloroquine phosphate in managing PCT and its associated risks.

Summary:

  • Biochemical diagnoses in 134 patients confirmed porphyria cutanea tarda (PCT) is generally not a paraneoplastic dermatosis.
  • While rare, a hepatoma producing porphyrins could be indicated by irregular urinary porphyrin excretion with hepatic porphyria skin changes.
  • Patients with long-standing PCT and liver cirrhosis exhibit a higher incidence of hepatocellular carcinoma compared to cirrhotics without PCT.
  • Chloroquine phosphate therapy may potentially prevent the progression of liver disease in PCT patients towards hepatocellular carcinoma.

Impact:

  • Clarifies that PCT is not typically a paraneoplastic syndrome, reducing diagnostic confusion.
  • Highlights a potential increased risk of hepatocellular carcinoma in long-term PCT patients with liver cirrhosis.
  • Suggests chloroquine phosphate as a potential therapeutic strategy to mitigate cancer risk in PCT patients.

Related Experiment Videos